Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for cognitive impairment and visual hallucinations in Parkinson's disease
NL-OMON32454Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of galantamine in Parkinson's disease (PD), sponsored by University Medical Center Groningen. Primary endpoint: Cognition and neuropsychiatric symptoms. Started Jul 2019; status: active, not recruiting.
02
Drugs
galantamine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON32454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32454.